Repurposing methuosis-inducing anticancer drugs for anthelmintic therapy.

Area of Science:

• Parasitology
• Oncology
• Drug Discovery

Background:

• Drug-resistant parasitic nematodes present significant challenges in agriculture, veterinary medicine, and human health.
• Existing anthelmintic treatments face limitations due to emerging resistance.
• Parasitic nematodes share molecular pathways with cancerous cells, suggesting potential for cross-disciplinary therapeutic strategies.

Purpose of the Study:

• To propose an innovative therapeutic paradigm for combating drug-resistant parasitic nematodes.
• To explore the repurposing of methuosis-inducing anticancer drugs as novel anthelmintics.
• To highlight shared molecular mechanisms between nematode infections and cancer.

Main Methods:

• Review of existing literature on drugs/chemicals inducing methuosis in cancer cells and their effects on nematodes.
• Analysis of Structure-Activity Relationships (SAR) for methuosis-inducing small molecules.
• Identification of shared cellular responses to vacuole-inducing agents in nematodes and cancer cells.

Main Results:

• Several anticancer drugs that induce methuosis (characterized by large vacuole accumulation and rupture) demonstrate efficacy against nematodes.
• The mechanism of methuosis provides a common pathway for cell death in both parasitic nematodes and cancerous cells.
• Structure-activity relationship analysis reveals key molecular features of effective methuosis inducers.

Conclusions:

• Repurposing methuosis-inducing anticancer drugs represents a promising strategy for developing broad-spectrum anthelmintics.
• This approach may lead to the discovery of novel therapeutic agents effective against drug-resistant nematodes.
• Understanding shared molecular mechanisms can advance treatments for both parasitic diseases and cancer.